Related Experiment Video
Updated: May 4, 2026
08:42
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
2.5K
Immunotherapy for colorectal cancer
Shigeo Koido1, Toshifumi Ohkusa1, Sadamu Homma1
1Shigeo Koido, Toshifumi Ohkusa, Kazuki Takakura, Keisuke Saito, Zensho Ito, Hiroko Kobayashi, Mikio Kajihara, Kan Uchiyama, Seiji Arihiro, Hisao Tajiri, Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Chiba 277-8567, Japan.
World Journal of Gastroenterology
|January 1, 2014
Summary
Immunotherapy offers a promising strategy to improve outcomes for advanced colorectal cancer (CRC) by enhancing cytotoxic T lymphocytes. This review explores various immunotherapy approaches and their potential in clinical trials for CRC treatment.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Colorectal cancer (CRC) incidence is increasing, with poor prognosis for recurrent or metastatic disease.
- Current treatments like chemotherapy and radiation have limitations for advanced CRC.
- There is a critical need for novel strategies to improve patient survival rates.
Purpose of the Study:
- To review the role of immunotherapy in inducing cytotoxic T lymphocytes for colorectal cancer.
- To discuss major immunotherapeutic approaches for CRC currently in clinical trials.
- To explore combination therapies and challenges like tumor escape mechanisms.
Main Methods:
- Literature review of immunotherapy strategies for colorectal cancer.
- Analysis of clinical trial data for various immunotherapeutic approaches.
- Discussion of mechanisms of action and clinical potential.
Main Results:
- Immunotherapy can enhance cytotoxic T lymphocytes, crucial for anti-tumor immunity.
- Several immunotherapeutic approaches, including vaccines and cell therapies, are under investigation.
- Combination therapies show potential but face challenges from tumor resistance.
Conclusions:
- Immunotherapy represents a vital frontier in treating advanced colorectal cancer.
- Further research and clinical trials are essential to overcome treatment resistance.
- Integrating immunotherapy holds promise for significantly improving CRC patient outcomes.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:49Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K